Keywords: Chagas’ disease, leishmaniasis, chemotherapy, amiodarone
|
Copyright © 2008 Mondolfi et al, publisher and licensee Dove Medical Press Ltd. Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug Correspondence: A E Paniz-Mondolfi Department of Pathology and Laboratory Medicine, St. Luke’s - Roosevelt - Beth Israel Medical Center, 1111 Amsterdam Avenue, New York, NY 10026, USA Tel + 1 917 355 7530 Fax + 1 212 600 1840 Email ap2647/at/columbia.edu | ||||
Abstract The occurrence of mixed infections of Trypanosoma cruzi and Leishmania spp. is becoming a common feature in Central and South America due to overlapping endemic areas. Unfortunately, the possibilities for treating flagellated kinetoplastid infections are still very limited and most of the available drugs exhibit severe side effects. Although the development of new drugs for Leishmania has markedly improved in the last years, the tendency is still to employ antimonial compounds. On the other hand, treatment for Chagas’ disease is only available for the acute phase with no effective therapeutical options for chronic stage disease. The following case report substantiates the recently discovered effect of amiodarone as a nonconventional antiparasitic drug, particularly against Leishmania, breaching a new perspective in the therapeutic management of these important infectious parasitic diseases. Keywords: Chagas’ disease, leishmaniasis, chemotherapy, amiodarone | ||||